Integration of endocannabinoid signaling into the neural network regulating stress-induced activation of the Hypothalamic-pituitary-Adrenal axis

Current Topics in Behavioral Neurosciences

Volumn 1, Issue , 2009, Pages 289-306

  Gorzalka, Boris B ^a   Hill, Matthew N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

2 AG; Adrenal; Amygdala; Anandamide; Cannabinoid; Corticosterone; FAAH; HPA axis; PVN; Stress

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUCOCORTICOID;

ANIMAL; DRUG EFFECT; FEEDBACK SYSTEM; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENDOCANNABINOIDS; FEEDBACK, PHYSIOLOGICAL; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 79952115483     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/978-3-540-88955-7_12     Document Type: Article

References (96)

1. Armario A. The hypothalamic-pituitary-adrenal axis: what can it tell us about stressors? CNS Neurol Disord Drug Target. 2006;5:485-501.
2. Aso E, Ozaita A, Valdizan EM et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB(1) knockout mice. J Neurochem 2008;105:565-572
3. Bain MJ, Dwyer SM, Rusak B. Restraint stress affects hippocampal cell proliferation differently in rats and mice. Neurosci Lett. 2004;368:7-10.
4. Barna I, Zelena D, Arszovszki AC et al. The role of endogenous cannabinoids in the hypothalamopituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 2004;75:2959-2970.
5. Bhatnagar S, Huber R, Nowak N et al. Lesions of the posterior paraventricular thalamus block habituation of hypothalamic-pituitary-adrenal responses to repeated restraint. J Neuroendocrinol. 2002;14:403-410.
6. Bisogno T, Berrendero F, Ambrasino G et al. Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological functions. Biochem Biophys Res Commun. 1999;256:377-380.
7. Bisogno T, Melck D, Bobrov MY et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoidreceptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000;351:817-824.
8. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav. 2005;81:224-238.
9. Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol. 2005;78:1192-1197.
10. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. 1997;17:1226-1242.
11. Carrier EJ, Kearn CS, Barkmeier AJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004;65:999-1007.
12. Carter RN, Pinnock SB, Herbert J. Does the amygdala modulate adaptation to repeated stress? Neuroscience. 2004;126:9-19.
13. Cole MA, Kalman BA, Pace TW et al. Selective blockade of the mineralocorticoid receptor impairs hypothalamic-pituitary-adrenal axis expression of habituation. J Neuroendocrinol. 2000;12:1034-1042.
14. Cota D, Marsicano G, TschopMet al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-431.
15. Cota D, Steiner MA, Marsicano G et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2007;148:1574-1581.
16. Dallman MF, Akana SF, Levin N et al. Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Ann NY Acad Sci. 1994;746:22-31.
17. De Catanzaro D, Gorzalka BB. Postpubertal social isolation and male sexual behavior in rodents: Facilitation or inhibition is species-dependent. Anim Learn Behav. 1979;7:555-561.
18. Deutsch DG, Ueda N, Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostag Leukotr Ess Fatty Acids. 2002;66:201-210.
19. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
20. Di S, Malcher-Lopes R, Halmos KC et al. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci. 2003;23:4850-4857.
21. Di S, Malcher-Lopes R, Marcheselli VL et al. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology. 2005;146:4292-4301.
22. Di Marzo V, Melck D, Bisogno T et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998;21:521-528.
23. Dinh TP, Carpenter D, Leslie FM et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99:10819-10824.
24. Diorio D, Viau V, Meaney MJ. The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci. 1993;13:3839-3847.
25. Doyon C, Denis RG, Baraboi ED et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes. 2006;55:3403-3410.
26. Evanson NK, Ulrich-Lai YM, Furay AR et al. (2007) Hypothalamic paraventricular cannabinoid receptor signaling in fast feedback inhibition of the hypothalamic-pituitary-adreanl response to acute restraint stress. Soc Neurosci. Abstr 197.5
27. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. 1998;38:179-200.
28. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83:1017-1066.
29. Fride E, Suris R, Weidenfeld J et al. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav Pharmacol. 2005;16:431-440.
30. Galiegue S, Mary S, Marchand J et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
31. 1 receptor blockade rapidly enhances the hormonal response to restraint. Soc Neurosci. Abstr 563.8
32. Gong JP, Onaivi ES, Ishiguro H et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071:10-23.
33. Gonzalez S, Manzanares J, Berrendero F et al. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology. 1999;70:137-145.
34. Gorzalka BB, Hill MN. Cannabinoids, reproduction and sexual behavior. Annu Rev Sex Res. 2006;17:132-161.
35. Gorzalka BB, Hill MN, Hillard CJ. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci Biobehav Rev 2008;32:1152-1160.
36. Haller J, Varga B, Ledent C et al. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J NeuroSci. 2004;19:1906-1912.
37. Hanus L, Abu-Lafi S, Fride E et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001;98:3662-3665.
38. Hao S, Avraham Y, Mechoulam R et al. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol. 2000;392:147-156.
39. Herkenham M, Lynn AB, Johnson MR et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563-583.
40. Herman JP, Tasker JG, Ziegler DR et al. Local circuit regulation of paraventricular nucleus stress integration: glutamate-GABA connections. Pharmacol Biochem Behav. 2002;71:457-468.
41. Herman JP, Figueiredo H, Mueller NK et al. Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol. 2003;24:151-180.
42. Herman JP, Ostrander MM, Mueller NK et al. Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1201-1213.
43. Hill MN, Ho WS, Sinopoli KJ et al. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology. 2006;31:2591-2599.
44. Hill MN, Morrish AC, McLaughlin RJ et al. (2007) Endogenous cannabinoids regulate habituation to stress. Soc Neurosci. Abstr 197.4
45. 1 receptor binding in the hippocampus. Hippocampus. 2008;18:221-226.
46. Hill MN, McLaughlin RJ, Morrish AC et al (2009a) Suppression of amygdalr endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology (in press).
47. Hill MN, Miller GE, Carrier EJ et al (2009b) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology (in press).
48. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther. 2000;294:27-32.
49. Hohmann AG, Suplita RL, Bolton NM et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435:1108-1112.
50. Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids. 2000;108:53-70.
51. Isbell H, Gorodetzsky CW, Jasinski D et al. Effects of (-) delta-9-tetrahydrocannabinol in man. Psychopharmacology. 1967;11:184-188.
52. Jaferi A, Bhatnagar S. Corticosterone can act at the posterior paraventricular thalamus to inhibit hypothalamic-pituitary-adrenal activity in animals that habituate to repeated stress. Endocrinology. 2006;147:4917-4930.
53. Kamprath K, Marsicano G, Tang J et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci. 2006;26:6677-6686.
54. Korte SM, Koolhaas JM, Wingfield JC et al. The Darwinian concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and disease. Neurosci Biobehav Rev. 2005;29:3-38.
55. Lamota L, Bermudez-Silva FJ, Marco EM et al. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology. 2008;54:194-205.
56. Malcher-Lopes R, Di S, Marcheselli VS et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci. 2006;26:6643-6650.
57. Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: A non-genomic anti-inflammatory switch. Eur J Pharmacol. 2008;583:322-339.
58. Manzaneres J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 1999;839:173-179.
59. McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism. 2005;54:20-23.
60. Melia KR, Ryabinin AE, Schroeder R et al. Induction and habituation of immediate early gene expression in rat brain by acute and repeated restraint stress. J Neurosci. 1994;14:5929-5938.
61. Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 2000;21:1735-1742.
62. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
63. Nakazi M, Bauer U, Nickel T et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:80-84.
64. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 2001;29:729-738.
65. Pagotto U, Marsicano G, Fezza F et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 2001;86:2687-2696.
66. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 1999;65:637-644.
67. Patel S, Roelke CT, Rademacher DJ et al. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 2004;145:5431-5438.
68. Patel S, Roelke CT, Rademacher DJ et al. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J NeuroSci. 2005;21:1057-1069.
69. Pecoraro N, Dallman MF, Warne JP et al. From Malthus to motive: how the HPA axis engineers the phenotype, yoking needs to wants. Prog Neurobiol. 2006;79:247-340.
70. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873-884.
71. Porter AC, Sauer JM, KniermanMD et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002;301:1020-1024.
72. Rademacher DJ, Meier SE, Shi L et al. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology. 2008;54:108-116.
73. Radley JJ, Arias CM, Sawchenko PE. Regional differentiation of the medial prefrontal cortex in regulating adaptive responses to acute emotional stress. J Neurosci. 2006;26:12967-12976.
74. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol. 2003;140:790-801.
75. Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152:984-986.
76. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22:565-572.
77. Schulkin J, Gold PW, McEwen BS. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: Implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology. 1998;23:219-243.
78. Steiner MA, Marsicano G, Nestler EJ et al. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology. 2008;33:54-67.
79. Succu S, Mascia MS, Sanna F et al. The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats. Behav Brain Res. 2006;169:274-281.
80. Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97.
81. Sun Y, Alexander SP, Kendall DA et al. Cannabinoids and PPARalpha signalling. Biochem Soc Trans. 2006;34:1095-1097.
82. Tsou K, Brown S, Sanudo-Pena MC et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393-411.
83. Uchigashima M, Narushima M, Fukaya M et al. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 2007;27:3663-3676.
84. Ueda N. Endocannabinoid hydrolases. Prostaglandins Oth Lipid M. 2002;68-69:521-534.
85. Uriguen L, Perez-Rial S, Ledent C et al. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology. 2004;46:966-973.
86. Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329-332.
87. Vaughan CW, Christie MJ. Retrograde signalling by endocannabinoids. Handbook Exp Pharmacol. 2005;168:367-383.
88. Viau V, Sawchenko PE. Hypophysiotropic neurons of the paraventricular nucleus respond in spatially, temporally, and phenotypically differentiated manners to acute vs. repeated restraint stress. J Comp Neurol. 2002;445:293-307.
89. Wade MR, Degroot A, Nomikos GG. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol. 2006;551:162-167.
90. Watanabe Y, Stone E, McEwen BS. Induction and habituation of c-fos and zif/268 by acute and repeated stressors. NeuroReport. 1994;5:1321-1324.
91. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 1994;59:110-112.
92. Wenger T, Jamali KA, Juaneda C et al. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun. 1997;237:724-728.
93. Wenger T, Fernandez-Ruiz JJ, Ramos JA. Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J Neuroendocrinol. 1999;11:873-878.
94. Wenger T, Ledent C, Tramu G. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology. 2003;78:294-300.
95. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296:678-682.
96. Yoshida T, Fukaya M, Uchigashima M et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci. 2006;26:4740-4751.